AnaptysBio, Inc.
ANAB
$59.43
-$0.56-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.47% | 327.75% | 146.00% | 17.21% | 10.49% |
| Total Depreciation and Amortization | 0.66% | 0.83% | 2.35% | 1.01% | 0.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.18% | 19.72% | 45.19% | 70.09% | 89.64% |
| Change in Net Operating Assets | -454.37% | 128.93% | -6,620.90% | -437.76% | 133.22% |
| Cash from Operations | -142.23% | 246.98% | -171.12% | -88.74% | 71.28% |
| Capital Expenditure | 51.43% | 99.62% | 65.71% | -18.18% | -29.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.18% | 352.29% | 76.10% | 1,612.74% | -78.32% |
| Cash from Investing | 135.62% | 350.03% | 76.19% | 1,590.70% | -78.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,734.83% | 2,100.36% | -99.66% | 45.35% | -64.24% |
| Repurchase of Common Stock | -- | -642.11% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.61% | -289.17% | 96.31% | -102.01% | -69.32% |
| Cash from Financing | 104.23% | -256.47% | -114.59% | -220.55% | -109.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.03% | 287.39% | -45.28% | -399.78% | -237.86% |